BC Week In Review | Dec 20, 2010
Company News

Inspire, Santen sales and marketing update

Santen launched Diquas diquafosol tetrasodium ophthalmic solution 3% in Japan to treat dry eye. The launch triggers a $1.3 million milestone payment to Inspire under a 1998 deal that granted Santen rights to develop and...
BC Week In Review | Aug 30, 2010
Company News

Inspire, Allergan deal

The companies mutually terminated Inspire's rights and obligations to co-promote dry eye treatment Restasis cyclosporine under a 2001 deal with Allergan for Restasis and Prolacria diquafosol tetrasodium. Inspire remains eligible for worldwide royalties through 2020...
BC Week In Review | Aug 16, 2010
Company News

Inspire, Santen sales and marketing update

The companies amended a 1998 deal under which Inspire granted Santen rights to develop and commercialize diquafosol tetrasodium in Japan and nine other Asian countries. Under the amendment, Santen was granted a license to manufacture...
BioCentury | Jul 5, 2010
Finance

2Q approvals

2Q approvals Company Approvals Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Japan approves Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH) Amgen Inc. (NASDAQ:AMGN) FDA approves Prolia denosumab to treat osteoporosis in postmenopausal women whoare at high risk...
BC Week In Review | Apr 19, 2010
Clinical News

Diquas diquafosol tetrasodium ophthalmic solution 3% regulatory update

Santen said the Japanese Ministry of Health, Labor and Welfare approved Diquas diquafosol tetrasodium ophthalmic solution 3% to treat dry eye. The company plans to launch the 3% ophthalmic solution formulation of uridine 5'-triphosphate (UTP)...
BioCentury | Apr 19, 2010
Finance

Regulatory milestones

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was off $0.09 to $54.87 last week after the company said the Japanese Ministry of Health, Labor and Welfare (MHLW) approved an NDA for Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria...
BC Extra | Apr 17, 2010
Company News

Japan approves Diquas for dry eye

Santen Pharmaceutical Co. Ltd. (Tokyo:4536; Osaka:4536) said the Japanese Ministry of Health, Labor and Welfare approved Diquas diquafosol tetrasodium ophthalmic solution 3% to treat dry eye. The company plans to launch the 3% ophthalmic solution...
BioCentury | Apr 5, 2010
Finance

1Q Approvals/1Q Setbacks

1Q Approvals/1Q Setbacks Selected first quarter product approvals Company Approval Acorda Therapeutics Inc. (NASDAQ:ACOR) FDA approves Ampyra dalfampridine (formerly Fampridine-SR) to improve walking ability in patients with multiple sclerosis (MS) Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) FDA...
BC Week In Review | Jan 25, 2010
Clinical News

Prolacria diquafosol tetrasodium: Phase III data

Top-line data from a North American Phase III (Trial 03-113) trial in 490 patients with a fluorescein staining score of 3 at baseline showed that Prolacria given 4 times daily missed the primary endpoint of...
BioCentury | Jan 25, 2010
Finance

Regulatory milestones

Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $2.50 (10%) to $28.12 on Friday after FDA approved an NDA for Ampyra dalfampridine (formerly Fampridine-SR ) to improve walking ability in patients with multiple sclerosis (MS). Acorda was up $2.86...
Items per page:
1 - 10 of 76